Halozyme Therapeutics(HALO) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Russell 2000 Stumbles Nearly 10% in Q1 – How Biggest IWM ETF Holdings Fared
Seeking AlphaMar 31 18:37 ET
Express News | Merck: FDA Has Set Pdufa Date of Sept 23
ReutersMar 27 11:00 ET
Express News | Merck Exec Says Hopes to Launch Subcutaneous Keytruda on Oct 1, Sees Peak Adoption About 18-24 Months After Approval - Interview
ReutersMar 27 11:00 ET
Express News | Merck: Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Shows Noninferior Pharmacokinetics Vs IV Keytruda in 3475a-D77 Trial
ReutersMar 27 11:00 ET
Express News | Merck: Applications for Subcutaneous Pembrolizumab Are Under Review in U.S. & Europe
ReutersMar 27 11:00 ET
Express News | Merck Exec Says Will Launch Subcutaneous Keytruda at Risk if Halozyme Patent Dispute Not Resolved yet - Interview
ReutersMar 27 11:00 ET

Comments

Noah Khos

Feb 18 06:42

$Halozyme Therapeutics (HALO.US)$ potential $60 post earnings report on 18th

1

Meltyy

May 22, 2024 15:41

Clinical Updates💉
⇒ $Larimar Therapeutics (LRMR.US)$ 🟢
‣ FDA removes partial clinical hold
‣ Nomlabofusp (CTI-1601) #FA
‣ Protein replacement therapy
‣ Interim data from OLE in Q4 '24 🔔
Clinical readouts 📢
⇒ $Citius Pharmaceuticals (CTXR.US)$ 🟢
‣ Positive Ph3 topline results
‣ Mino-Lok® #CLABSI #CRBSI
‣ Antibiotic lock solution
‣ Overall treatment success in 57.1% patients
Regulatory Update🎯
⇒ $Halozyme Therapeutics (HALO.US)$ $Bristol-Myers Squibb (BMY.US)$
‣ FDA Reassigned PDUFA data to 12/29/24
‣ Subcutane...

4

Moomoo AI

Feb 19, 2024 19:59

EPS growth outshines yearly share price gain, hinting at cautious market sentiment. Despite recent sell-off, long-term investors see 16% annual return over five years, suggesting sell-off may be an opportunity for those seeking long-term growth.

Halozyme Therapeutics' (NASDAQ:HALO) Investors Will Be Pleased With Their Impressive 107% Return Over the Last Five Years

Moomoo AI

Dec 25, 2023 19:09

The insider stock selling at Halozyme Therapeutics could raise concerns among shareholders. However, the fact that insiders maintain a considerable amount of shares might suggest some level of alignment between management and smaller shareholders.